PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9306621-0	1997	Efficacy of danazol in a patient with congenital protein-S deficiency: paradoxical evidence for decreased platelet activation with increased thrombin generation.	Danazol	12-19	coagulation factor II, thrombin	Homo sapiens	141-149	
489712-7	1979	3) Transferrin, antithrombin III, prothrombin, and plasminogen showed marked increases after administration of danazol and during pregnancy.	Danazol	111-118	coagulation factor II, thrombin	Homo sapiens	34-45	
9306621-6	1997	Both Prothrombin Fragment 1.2 and thrombin-antithrombin complexes were elevated post danazol therapy indicating continued clearance of generated thrombin.	Danazol	85-92	coagulation factor II, thrombin	Homo sapiens	8-16	
9306621-6	1997	Both Prothrombin Fragment 1.2 and thrombin-antithrombin complexes were elevated post danazol therapy indicating continued clearance of generated thrombin.	Danazol	85-92	coagulation factor II, thrombin	Homo sapiens	34-42	
9306621-7	1997	These data suggest that the protective effect provided by danazol in this patient with hereditary PS deficiency, may in large part be due to suppression of platelet activation by thrombin inhibition than simply through elevation of PS.	Danazol	58-65	coagulation factor II, thrombin	Homo sapiens	179-187